NCT05341349View on ClinicalTrials.gov

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

October 13, 2022

Primary Completion Date

March 6, 2026

Study Completion Date

March 6, 2027

Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8Melanoma of Unknown PrimaryMetastatic Malignant Neoplasm in the BrainMetastatic MelanomaMetastatic Mucosal MelanomaMetastatic Ocular MelanomaPathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions
BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

RADIATION

Stereotactic Radiosurgery

Undergo SRS

PROCEDURE

Tumor Treating Fields Therapy

Undergo TTFields

Trial Locations (1)

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

NovoCure Ltd.

INDUSTRY

lead

Emory University

OTHER